However, the absence of a negative trend on these assessments would be an important part of the overall benefit/risk assessment of clazosentan in patients with aSAH.
← all excerpts
The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
1
—
—